Evaluation of the antibody response and adverse reactions to the BNT162b2 vaccine of participants with prior COVID-19 infection in Japan

抄録

[Objective] The aim of this study is to evaluate the antibody titer and adverse reactions to the BNT162b2 vaccine among participants with prior COVID-19 infection in Japan. [Methods] The data for this study was collected between April 15, 2021, and June 9, 2021. All of the hospital staff who received the BNT162b2 vaccine were included in this study and were sorted into either a prior infection group or a control group. We collected the data of adverse reactions through self-reporting and calculated the anti-SARS-CoV-2 spike-specific antibody titer for all participants. [Results] The antibody titer of the prior-infection group in first antibody test was significantly higher than that of the control group in the second antibody test. There was no significant difference in adverse reactions between the prior infection group receiving its first vaccination and the control group receiving its second vaccination. [Conclusions] Our study shows that the antibody response following the first vaccination in the prior COVID-19 infection group was comparable to that of the second vaccination in the control group;however, the evaluation of adverse reactions was inadequate and further, large-scale studies are needed.